Joy Duemke: Optimizing Stem Cell Collection for Gene Therapy Success
Joy Duemke, Director of Marketing and Commercialization in North America at Terumo Blood and Cell Technologies, shared a post on LinkedIn:
“Gene therapy is creating new possibilities for patients with genetic hemoglobinopathies, but collecting sufficient, high-quality hematopoietic progenitor cells (HPCs) can be particularly challenging due to the impact of the underlying disease on mobilization.
Optimizing these procedures is an important step in helping more patients benefit from these therapies.
We appreciate AABB and presenting faculty, including Dr. John Manis, behind ‘Optimizing Apheresis Starting Material Collections for Stem Cell Gene Therapy Manufacturing for Patients with Genetic Hemoglobinopathies’ for tackling these challenges head-on to help ensure more SCD and thalassemia patients can benefit from these breakthrough therapies.
Register for the program on Wednesday, August 12, from 2:00–3:00 PM ET.”
Stay updated with Hemostasis Today.
-
Jul 21, 2026, 15:02Sham Zamil: The Role of ABO Compatibility in Platelet Pooling
-
Jul 21, 2026, 13:43Dima Shulkin: Assessing AI-Driven Blood Test Screening for Colorectal Cancer
-
Jul 21, 2026, 13:24Benoit Mores: National Initiative Targets Better Cardiovascular Outcomes
-
Jul 21, 2026, 13:10Paolo Zamboni: Chronic Cerebrospinal Venous Insufficiency Hypothesis in Multiple Sclerosis
-
Jul 21, 2026, 13:05Danai Poutakidou։ The Diagnostic Pitfalls of Unexpected PT/INR Prolongation
-
Jul 21, 2026, 13:00Kefah Mokbel: Beyond Thromboprophylaxis – Enoxaparin’s Emerging Anticancer Signal
-
Jul 21, 2026, 12:56Emmanuel Velazquez-Alvarez: Bridging Innovation and Clinical Practice
-
Jul 21, 2026, 12:53Sandrine Bouteille: A Milestone Presentation at ISTH 2026
-
Jul 21, 2026, 12:40Kalled Musallam: A Comprehensive Review of Thalassemia